Subscribe
shutterstock_1843221310_maxshot_pl
MAXSHOT.PL / Shutterstock.com
29 April 2021AmericasAlex Baldwin

GSK claims Amgen v Sanofi decision “threatens” innovation

GlaxoSmithKline (GSK) has submitted an amicus  brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fed Circ invaded jury’s role in Repatha case, says Amgen
25 November 2021   Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.
Generics
GSK responds to Teva’s ‘skinny’ label rehearing petition
9 December 2021   Following a substantial push from generics companies to reverse the GSK v Teva “skinny” label ruling, GlaxoSmithKilne has added its response to the petition to rehear the case yet again.
Americas
Fed Circ rejects Sanofi’s bid to resurrect Lantus patents
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Fed Circ invaded jury’s role in Repatha case, says Amgen
25 November 2021   Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.
Generics
GSK responds to Teva’s ‘skinny’ label rehearing petition
9 December 2021   Following a substantial push from generics companies to reverse the GSK v Teva “skinny” label ruling, GlaxoSmithKilne has added its response to the petition to rehear the case yet again.
Americas
Fed Circ rejects Sanofi’s bid to resurrect Lantus patents
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.

More on this story

Americas
Fed Circ invaded jury’s role in Repatha case, says Amgen
25 November 2021   Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.
Generics
GSK responds to Teva’s ‘skinny’ label rehearing petition
9 December 2021   Following a substantial push from generics companies to reverse the GSK v Teva “skinny” label ruling, GlaxoSmithKilne has added its response to the petition to rehear the case yet again.
Americas
Fed Circ rejects Sanofi’s bid to resurrect Lantus patents
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent